COYA
HEALTHCARECoya Therapeutics Inc
$4.24-0.01 (-0.24%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving COYA Today?
No stock-specific AI insight has been generated for COYA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.71$7.75
$4.24
Fundamentals
Market Cap$99M
P/E Ratio—
EPS$-1.27
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-2.7%
Debt / Equity—
Trading
Volume75K
Avg Volume (10D)—
Shares Outstanding23.5M
COYA News
20 articles- NanoViricides to Participate at D. Boral Capital Global Conference in NYCYahoo Finance·May 7, 2026
- NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDAYahoo Finance·May 6, 2026
- Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALSYahoo Finance·Apr 9, 2026
- Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent DirectorYahoo Finance·Apr 2, 2026
- Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring TherapyYahoo Finance·Mar 18, 2026
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial ResultsYahoo Finance·Mar 16, 2026
- Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Feb 25, 2026
- Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in WebinarMarketbeat·Feb 17, 2026
- Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical TrialYahoo Finance·Feb 10, 2026
- Coya Therapeutics to sell 2.522M shares at $4.40 in private placementYahoo Finance·Jan 31, 2026
- Coya Therapeutics Announces $11.1 Million Private PlacementYahoo Finance·Jan 30, 2026
- Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to StockholdersYahoo Finance·Jan 20, 2026
- Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia PatientsYahoo Finance·Jan 8, 2026
- Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)Yahoo Finance·Jan 5, 2026
- Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Yahoo Finance·Dec 23, 2025
- Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALSYahoo Finance·Dec 9, 2025
- ReAlta Life Sciences Designates Dr. Howard Berman as Executive ChairmanYahoo Finance·Dec 2, 2025
- Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials ConferencesYahoo Finance·Nov 25, 2025
- RoboMarkets expands trading opportunities with over 1,300 additional US stocks and ETFsYahoo Finance·Nov 20, 2025
- Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate UpdateYahoo Finance·Nov 12, 2025
All 20 articles loaded
Price Data
Open$4.31
Previous Close$4.25
Day High$4.31
Day Low$4.15
52 Week High$7.75
52 Week Low$3.71
52-Week Range
$3.71$7.75
$4.24
Fundamentals
Market Cap$99M
P/E Ratio—
EPS$-1.27
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-2.7%
Debt / Equity—
Trading
Volume75K
Avg Volume (10D)—
Shares Outstanding23.5M
About Coya Therapeutics Inc
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—